The proportion of patients with DM enrolled in the four trials was 23% in the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) study, 40% in the Rivaroxaban Once-daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation (ROCKET-AF) study, 25% in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) study, and 36% in the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation (ENGAGE-AF TIMI 48) study [14,15,16,17]. This evidence concerns the gene F10 and Thromboembolism.